BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 21,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 21,000 shares of the company’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $96.81, for a total value of $2,033,010.00. Following the completion of the sale, the chief executive officer owned 87,209 shares of the company’s stock, valued at approximately $8,442,703.29. The trade was a 19.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The shares were sold at an average price of $97.23, for a total value of $7,000,560.00.
• On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The shares were sold at an average price of $97.46, for a total value of $1,656,820.00.
• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The shares were sold at an average price of $98.12, for a total value of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total transaction of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total value of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total transaction of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The stock was sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total value of $2,886,600.00.

BioNTech Stock Performance

Shares of NASDAQ:BNTX traded down $1.81 on Tuesday, hitting $95.83. 899,354 shares of the company were exchanged, compared to its average volume of 1,088,477. The stock’s 50 day moving average price is $98.94 and its 200 day moving average price is $95.06. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $24.23 billion, a P/E ratio of -12.24 and a beta of 1.25.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. During the same period in the previous year, the company posted ($1.60) earnings per share. BioNTech’s revenue for the quarter was down 59.5% compared to the same quarter last year. Sell-side analysts predict that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. BMO Capital Markets cut shares of BioNTech from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $128.00 to $105.00 in a research report on Tuesday, September 8th. Citigroup lowered their price objective on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th. Canaccord Genuity Group dropped their target price on BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a report on Monday, August 31st. Morgan Stanley dropped their price target on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 8th. Finally, Berenberg Bank set a $140.00 target price on BioNTech in a report on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Institutional Investors Weigh In On BioNTech

A number of large investors have recently added to or reduced their stakes in BNTX. Integrated Wealth Concepts LLC acquired a new stake in shares of BioNTech in the second quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd grew its holdings in BioNTech by 1,012.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock valued at $53,000 after buying an additional 506 shares during the period. Vestcor Inc acquired a new position in BioNTech during the fourth quarter worth approximately $153,000. Rockefeller Capital Management L.P. raised its position in shares of BioNTech by 328.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after buying an additional 1,423 shares during the period. Finally, Quantum Portfolio Management LLC purchased a new position in shares of BioNTech in the 1st quarter worth about $203,000. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.